Work

A Phase 1 Trial of Lenalidomide (REVLIMID®) with Bortezomib (VELCADE®) in Relapsed and Refractory Multiple Myeloma.

Year: 2005

Type: article

Source: Blood

DOI: 10.1182/blood.v106.11.365.365

Authors: Paul Richardson, R. Schlossman, N. Munshi, D. Avigan, S. Jagannath, M. Alsina, D. Doss, M. McKenney, K. Hande, M. Farrell, S. Gorelik, K. Colson, D. Warren, L. Lunde, R. Michelle, G. Cole, C. Mitsiades, T. Hideshima, T. Myers, R. Knight, K. Anderson

Institutions: Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Saint Vincent's Catholic Medical Center, Moffitt Cancer Center, Takeda Oncology (United States), Celgene (United States)

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2549560782

FWCI: 5.845

Cites:

Cited by: 35

Related to: 10